Kezar Life Sciences Inc Topline Results from the MISSION Phase 2 Clinical Trial Evaluating Zetomipzomib - Corporate Call Transcript
Welcome to Kezar Life Sciences 2022 topline data presentation of the MISSION Phase 2 clinical trial. Today's presentation will be followed by a question-and-answer session. I would now like to hand the call over to John Fowler, Chief Executive Officer and Co-Founder of Kezar Life Sciences. Go ahead, John.
Thank you for the introduction, Alex, and good afternoon, everyone. Thank you all for joining us today as we present the topline data for MISSION, our clinical trial investigating zetomipzomib for the treatment of lupus nephritis.
Here are our disclaimers.
Now, the second quarter has been very busy for us, having completed not one but two clinical trials. As you read from our press release, we have exciting, positive and meaningful results to share with you today, so I'm not going to delay jumping into the MISSION trial data. But here is the outline for the next hour.
Kezar just celebrated its seventh birthday, and it's been a true pleasure to work with my dear friend
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
